20 articles
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
New study finds 27% of patients with treatment-resistant hypertension have elevated cortisol levels that could explain medication failures.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
When the DNA-repair gene EXO1 is overproduced, it damages DNA instead of fixing it—exposing a hidden vulnerability in multiple cancers.
Scientists discover why identical cancer treatments work for some patients but fail for others, revealing hidden drug reservoirs in cells.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
Breakthrough antibodies completely prevent EBV infection in lab models, offering hope against virus linked to cancer and chronic disease.
